Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Inclusion Criteria: * Age between 18 and 70 years old * Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB\> or = 4 cm to IV, according to FIGO classification) histologically proven * Measurable lesions,clinically and by MRI assessed * PS-WHO \< or = 2 ou Karnofsky Index \>70 per cent * Life expectancy \> 3 months * Hematologic function: leukocytes \< or = 3 G/l, polynuclear neutrophil leukocytes \> or = 1.5 G/l, platelets \> or = 100 G/l, hemoglobin \> or = 10 g/dl * Hepatic function: ASAT and ALAT \< 2.5 ULN * Renal function: creatininemia \< 1.5 ULN, clearance \> 60 ml/min * No prior chemotherapy or radiotherapy * Contraception * Written informed consent signed Exclusion Criteria: * Stage IB \< 4 cm or IVB * Other histology than epidermoid or adenocarcinoma * Distant metastases, including sus-clavicular adenopathy * Contraindication to MRI * Pregnant or lactating woman * Auto-immune disease * Peripheric neuropathy, autograft or homograft, psychiatric disease * Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ) * Active infection * Other clinical trial with an experimental drug * Known positive serology (HIV, HbC, HbS)